Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Özgür Yaldizli"'
Autor:
Perrine Janiaud, Chiara Zecca, Anke Salmen, Pascal Benkert, Sabine Schädelin, Annette Orleth, Lilian Demuth, Aleksandra Maleska Maceski, Cristina Granziera, Johanna Oechtering, David Leppert, Tobias Derfuss, Lutz Achtnichts, Oliver Findling, Patrick Roth, Patrice Lalive, Marjolaine Uginet, Stefanie Müller, Caroline Pot, Robert Hoepner, Giulio Disanto, Claudio Gobbi, Leila Rooshenas, Matthias Schwenkglenks, Mark J. Lambiris, Ludwig Kappos, Jens Kuhle, Özgür Yaldizli, Lars G. Hemkens
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-12 (2024)
Abstract Background Treatment decisions for persons with relapsing–remitting multiple sclerosis (RRMS) rely on clinical and radiological disease activity, the benefit-harm profile of drug therapy, and preferences of patients and physicians. However
Externí odkaz:
https://doaj.org/article/2dbdfb286bde4ad5a8fa355b8dcd0b9d
Autor:
Jannis Müller, Izanne Roos, Tomas Kalincik, Johannes Lorscheider, Edoardo Galli, Pascal Benkert, Sabine Schädelin, Sifat Sharmin, Maximilian Einsiedler, Peter Hänni, Jürg Schmid, Jens Kuhle, Tobias Derfuss, Cristina Granziera, Tjalf Ziemssen, Timo Siepmann, Özgür Yaldizli
Publikováno v:
Brain and Behavior, Vol 14, Iss 5, Pp n/a-n/a (2024)
Abstract Background In patients with relapsing remitting multiple sclerosis (RRMS) on low‐efficacy disease modifying therapies (DMT), the optimal strategy on how to escalate treatment once needed, remains unknown. Methods: We studied RRMS patients
Externí odkaz:
https://doaj.org/article/86d1f84466b94b22a7d83b8760f676f9
Autor:
Manina M. Etter, Tomás A. Martins, Laila Kulsvehagen, Elisabeth Pössnecker, Wandrille Duchemin, Sabrina Hogan, Gretel Sanabria-Diaz, Jannis Müller, Alessio Chiappini, Jonathan Rychen, Noëmi Eberhard, Raphael Guzman, Luigi Mariani, Lester Melie-Garcia, Emanuela Keller, Ilijas Jelcic, Hans Pargger, Martin Siegemund, Jens Kuhle, Johanna Oechtering, Caroline Eich, Alexandar Tzankov, Matthias S. Matter, Sarp Uzun, Özgür Yaldizli, Johanna M. Lieb, Marios-Nikos Psychogios, Karoline Leuzinger, Hans H. Hirsch, Cristina Granziera, Anne-Katrin Pröbstel, Gregor Hutter
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-21 (2022)
Both acute and chronic COVID-19 disease (also known as long-COVID) may affect the central nervous system. Here authors characterize the immunological profile of peripheral blood and cerebrospinal fluid of COVID-19 patients in order to identify the ma
Externí odkaz:
https://doaj.org/article/f0470cc90c504832a493429d193b5b41
Autor:
Nuria Cerdá-Fuertes, Sara Nagy, Sabine Schaedelin, Tim Sinnecker, Esther Ruberte, Athina Papadopoulou, Jens Würfel, Jens Kuhle, Özgür Yaldizli, Ludwig Kappos, Tobias Derfuss, Bernhard F. Décard
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Background: Clinical and radiological signs of recurring disease activity (RDA) have been described in patients with multiple sclerosis (pwMS) after discontinuation of fingolimod (FGL). Objective: To describe frequency, severity and potential risk fa
Externí odkaz:
https://doaj.org/article/8eb5ba1fd68e4922a413b3d4dcf1ee58
Autor:
Tim Sinnecker, Sabine Schädelin, Pascal Benkert, Esther Ruberte, Michael Amann, Johanna M. Lieb, Yvonne Naegelin, Jannis Müller, Jens Kuhle, Tobias Derfuss, Ludwig Kappos, Jens Wuerfel, Cristina Granziera, Özgür Yaldizli
Publikováno v:
NeuroImage: Clinical, Vol 36, Iss , Pp 103148- (2022)
Background: A change in MRI hardware impacts brain volume measurements. The aim of this study was to use MRI data from multiple sclerosis (MS) patients and healthy control subjects (HCs) to statistically model how to adjust brain atrophy measures in
Externí odkaz:
https://doaj.org/article/52d8109081ac484e8be3e9af80d62d71
Autor:
Laura Sander, Antal Horvath, Simon Pezold, Simon Andermatt, Michael Amann, Tim Sinnecker, Maria J. Wendebourg, Eva Kesenheimer, Özgür Yaldizli, Ludwig Kappos, Cristina Granziera, Jens Wuerfel, Philippe Cattin, Regina Schlaeger
Publikováno v:
Frontiers in Neuroscience, Vol 14 (2020)
Background: Brainstem-mediated functions are impaired in neurodegenerative diseases and aging. Atrophy can be visualized by MRI. This study investigates extrinsic sources of brainstem volume variability, intrinsic sources of anatomical variability, a
Externí odkaz:
https://doaj.org/article/653b7ec6894b4207af60a1758e990387
Autor:
Marco Kaufmann, Milo Alan Puhan, Jens Kuhle, Özgür Yaldizli, Tomas Magnusson, Christian P. Kamm, Pasquale Calabrese, Viktor von Wyl
Publikováno v:
Frontiers in Neurology, Vol 10 (2019)
Background: When population-based databases are unavailable, nationwide assessments of the disease burden of multiple sclerosis (MS) resort to clinical, administrative or convenience-sampled data sources, which may produce results of limited external
Externí odkaz:
https://doaj.org/article/29b538f9632c4bc28e68ea62fd81937a
Autor:
Oliver Findling, Heiko Rust, Özgür Yaldizli, Dionne P. H. Timmermans, Alja Scheltinga, John H. J. Allum
Publikováno v:
Frontiers in Neurology, Vol 9 (2018)
Aims: To compare balance changes over time during the relapse phase of relapsing-remitting multiple sclerosis (RRMS) with balance control during the remitting phase.Methods: Balance control during stance and gait tasks of 24 remitting-phase patients
Externí odkaz:
https://doaj.org/article/c00c5c5bd8fd48189ef601c486647050
Autor:
Giulio Disanto, Pascal Benkert, Johannes Lorscheider, Stefanie Mueller, Jochen Vehoff, Chiara Zecca, Simon Ramseier, Lutz Achtnichts, Oliver Findling, Krassen Nedeltchev, Ernst-Wilhelm Radue, Till Sprenger, Christoph Stippich, Tobias Derfuss, Jean-François Louvion, Christian P Kamm, Heinrich P Mattle, Christoph Lotter, Renaud Du Pasquier, Myriam Schluep, Caroline Pot, Patrice H Lalive, Özgür Yaldizli, Claudio Gobbi, Ludwig Kappos, Jens Kuhle, SMSC Scientific Board
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0152347 (2016)
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic,
Externí odkaz:
https://doaj.org/article/5c7baa1ec4e24df999173aed779eb920
Autor:
Özgür Yaldizli, Norman Putzki
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 2 (2009)
Natalizumab reduced the rate of clinical relapse at one year by 68% and the risk of sustained progression of disability by 42—54% over 2 years in its pivotal phase III trial (AFFIRM) in relapsing—remitting multiple sclerosis (RRMS). Natalizumab i
Externí odkaz:
https://doaj.org/article/ac55ebbd9678419da2020a9b87054d61